Satoh Shin-ichi, Ikegaki Ichiro, Kawasaki Koh, Asano Toshio, Shibuya Masato
Scientific Affairs Dept., Asahi Kasei Pharma Corporation, 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo 101- 8101, Japan.
Curr Vasc Pharmacol. 2014;12(5):758-65. doi: 10.2174/1570161112666140613115813.
There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH). A number of pathological processes, in particular hemodynamic dysfunctions and inflammatory reactions, are thought to be related in the pathogenesis of delayed cerebral vasospasm and subsequent ischemic injury after SAH. This review focuses on fasudil's pleiotropic therapeutic effects: amelioration of hemodynamic dysfunction and inflammation, and discusses in detail the clinical studies on fasudil administered after the occurrence of SAH.
越来越多的证据表明，Rho激酶与心血管疾病有关，这使得Rho激酶成为治疗人类疾病的一个靶点。迄今为止，临床上唯一用于人类的Rho激酶抑制剂是法舒地尔，它已被用于预防蛛网膜下腔出血（SAH）手术后的脑血管痉挛及随后的缺血性损伤。一些病理过程，特别是血流动力学功能障碍和炎症反应，被认为与SAH后迟发性脑血管痉挛及随后的缺血性损伤的发病机制有关。本综述重点关注法舒地尔的多效性治疗作用：改善血流动力学功能障碍和炎症，并详细讨论SAH发生后给予法舒地尔的临床研究。
